Johnson & Johnson said it is starting its Phase 1/2a trial of its Covid-19 vaccine in the second half of July, earlier than initially planned.
The trial will evaluate patients' response to vaccination and immune response. It will involve 1,045 healthy adults aged 18 to 55, as well as adults aged 65 and above, J&J said.
The study will be held in the U.S. and Belgium, the company said.
|JNJ||JOHNSON & JOHNSON||162.34||+1.65||+1.03%|
J&J said it is in discussions with the National Institutes of Allergy and Infectious Diseases to start the vaccine's Phase 3 trial ahead of schedule, depending on the outcome of the Phase 1 studies and regulators' approval.
The company said it would supply more than one billion vaccine doses in 2021 if the vaccine is proven to be safe and effective.